Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.

Journal article

We investigated whether vaccination of healthy HIV-seronegative and HIV-1-seropositive antiretroviral therapy-treated subjects with recombinant modified vaccinia virus Ankara expressing an HIV-1 immunogen (MVA.HIVA) induced MVA-specific T cell responses. Using IFN-γ Elispot assays, we observed new or increased responses to MVA virus in 52% of HIV-seronegative subjects and 93% HIV-1 seropositive subjects; MVA-specific T cell frequencies were generally low and correlated poorly with T cell responses to the HIV-1 immunogen. In two vaccinees, responses were mapped to CD8+ T cell epitopes present in replication-competent vaccinia virus. These data support further evaluation of MVA as a viral vector for HIV-1 immunogens.

Authors: Howles, S; Guimarães-Walker, A; Yang, H; Hancock, G; di Gleria, K

• Publication status: Published
• Journal: Vaccine
• Volume: 28
• Issue: 45
• Pages: 7306-7312
• Publication date: 2010-10-01
• DOI: 10.1016/j.vaccine.2010.08.077
• EISSN: 1873-2518
• ISSN: 0264-410X
• Language: English
• Keywords: Interferon-gamma; Adolescent; AIDS Vaccines; Young Adult; Antiretroviral Therapy, Highly Active; Epitopes, T-Lymphocyte; HIV Infections; Humans; T-Lymphocytes; HIV-1; Immunity, Cellular; Adult; Genetic Vectors; Middle Aged; Vaccinia virus; Immunization, Secondary; HIV Seronegativity